Doctor Evidence To Be Subscription Software Platform For Meeting Abstracts For Leading Oncology Association
18 Sep, 2017, 17:35 BST
SANTA MONICA, California, Sept. 18, 2017 /PRNewswire/ -- Doctor Evidence (DRE), a global health technology and consulting company, has signed a contract with the American Society of Clinical Oncology, Inc. (ASCO®), the world's leading professional organization representing physicians who care for people with cancer, to digitize and host ASCO meeting abstracts in DRE's technology platform. This platform will be used for in-depth queries by researchers across abstracts with the capability to track data and changing research focus in the field of oncology over time. The product will be a subscription offering including new meeting abstracts as they become publicly available. Archived years of ASCO abstracts will also be available in the subscription offering.
The search platform will enable a series of features, including advanced term searching, concept identification, author analyses and linkage of threads presented in the abstracts as well as "parent/child" relationship timelines as abstracts are further developed into other works or published manuscripts by their authors. Novel features will permit users to search within and across abstracts comparing and analyzing methods, results, and trends. This central repository of all ASCO meeting abstracts will be made available concurrent with their release around the ASCO Annual Meeting and regional meetings as they occur. All meeting abstracts for the past 20 years will be available in the Search platform, making longitudinal investigations on research trends and evolving data readily available. Abstracts will be linked to published papers addressing the same clinical trial populations, so researchers can follow cohorts over time, avoid double counting patients, and conduct author analyses and networked searches. Additionally, and unique to this collaboration, will be the tagging of all data, terms and outcomes in each ASCO meeting abstract according to ASCO's proprietary oncology ontology.
"Our relationship with ASCO is predicated on our extensive experience digitizing clinical research data and building innovative technologies to support robust scientific investigations and sophisticated analyses," said Robert Battista, CEO of Doctor Evidence. "DRE's leadership in these areas make us an ideal platform for structuring and synthesizing this complex data to increase the agility of insights for the oncology research community."
About Doctor Evidence:
Doctor Evidence (DRE) is a health technology and consulting company utilizing state-of-the-art solutions that identify, synthesize, and analyze complex clinical research data into fit-to-purpose actionable knowledge. Resulting high quality evidence reviews provide guideline developers, academic researchers, medical providers, manufacturers, payers, and patients with evidence-based information to make timely and educated decisions on recommended treatment protocols, outcomes research, health economics, risk management, market access, reimbursement, value determinations, and burden of illness cost models. These methodologically rigorous reviews and analyses fully comply with accepted international standards to address the needs of patients, providers, and scientists worldwide. To learn more about Doctor Evidence, visit drevidence.com and GROWTHevidence.com.
Contact:
Sandra Zelman Lewis, PhD, Chief Guidelines Officer
slewis@doctorevidence.com
NOTE: ASCO® is a registered trademark of the American Society of Clinical Oncology, Inc. Used with permission. ASCO is not a partner or affiliate of Doctor Evidence and does not recommend or endorse any vendor, product, or service.
Logo: http://mma.prnewswire.com/media/397547/Doctor_Evidence_Logo.jpg
Related Links
SOURCE Doctor Evidence